Explore GeneDx Holdings Corp's Q4 2024 financial insights, revealing impressive revenue growth, improved net loss, and ongoing challenges in operational efficiency and legal matters.
Explore GeneDx Holdings Corp.'s latest 8-K filing, revealing critical stock and warrant details, including pricing and classifications for investors.
Explore GeneDx Holdings Corp.'s latest Form 8-K filing revealing crucial details about Class A common stock and warrants trading on NASDAQ. Key insights for investors.
Explore GeneDx Holdings Corp.'s 8-K report detailing stock and warrant information, including exercise prices and corporate changes as of January 2, 2025.